How is Halotestin taken?

Tablet strengths and route
StrengthTablet colourBottle sizes
2 mg1Peach100
5 mg1Light green100
10 mg1Green30 and 100

The Halotestin label gives a daily dose of 5 to 20 mg by mouth for complete replacement in the hypogonadal male, which it says will suffice in the majority of patients, taken singly or in three or four divided doses, from 2 mg, 5 mg and 10 mg tablets.1

Tablet strengths and route

The table is set at the top of the page

The label describes Halotestin only as a tablet for oral administration, with no mixing or syringe step.1 Among the sources found, buccal use appears only in Capponi 1985, a bioavailability study in which six subjects each took 10-mg fluoxymesterone tablets buccally and orally in a crossover.2

What the label gives for dose and schedule

For complete replacement in the hypogonadal male, the label gives 5 to 20 mg a day for most patients.1 The total daily oral dose may be given once or in three or four divided doses, and it varies with the individual, the condition and its severity.1 The label says priapism is indicative of excessive dosage and is indication for temporary withdrawal of the drug, and that liver function tests are to be obtained periodically because of the hepatotoxicity associated with 17-alpha-alkylated androgens.1

For delayed puberty in males, the label says to titrate from a low dose, monitor the skeleton and limit therapy to four to six months.1 The label gives no milligram dose or numeric steps for delayed puberty beyond titrating from a low dose.1

For palliative therapy of advanced inoperable breast cancer in women, the label gives 10 to 40 mg a day in total.1 Because of its short action, the label says fluoxymesterone is to be given in divided, rather than single, daily doses to ensure more stable blood levels.1

What trials gave

TrialDose and schedulePeopleLength
Ingle 20063Fluoxymesterone 10 mg orally twice a day for 1 year added to tamoxifen 20 mg a day for 5 years, against tamoxifen alone541 eligible postmenopausal women with resected ER-positive early breast cancer1 year of fluoxymesterone; median follow-up 11.4 years
Ingle 1988 and 1991 update45Fluoxymesterone 10 mg orally twice daily plus tamoxifen 10 mg orally twice daily, against tamoxifen alone; patients failing tamoxifen could later receive fluoxymesterone119 postmenopausal women with metastatic breast cancer per armNot stated
Tormey 19836Fluoxymesterone given orally twice a day at 7 mg/m2 body surface area, with tamoxifen given orally twice a day at 2 to 100 mg/m2, against tamoxifen alone108 women with metastatic breast cancer, 56 on the combination and 52 on tamoxifen aloneNot stated
Strickland 199372.5 mg oral fluoxymesterone dailyEighty-two short boys (71 with constitutional delay of growth and puberty, 11 with genetic short stature), with 34 untreated boys followed6 to 60 months
Loprinzi 19998Fluoxymesterone 10 mg orally twice a day, against dexamethasone 0. 75 mg four times a day or megestrol acetate 800 mg orally every dayPeople with cancer anorexia or cachexia (number not stated)Not stated
Brubaker 1982930 mg/day oral fluoxymesterone plus necessary transfusions, against transfusions alonePreviously untreated patients with anaemia (haemoglobin 10 g/dL or less): 16 with myelofibrosis and 13 with other myeloproliferative disorders; 24 could be evaluatedNot stated
French Cooperative Group 198610Fluoxymesterone or norethandrolone at 1 mg/kg/d or 0.2 mg/kg/d; four androgens at high doses in a second comparison110 patients with aplastic anaemia, and 125 others in the four-androgen comparisonNot stated

Strickland concluded that a daily oral dose of 2.5 mg of fluoxymesterone can be used to accelerate linear growth in boys with constitutional delay of growth and puberty and genetic short stature when needed to alleviate emotional problems secondary to slow growth and short stature, without fear of compromising final adult height.7 Loprinzi found fluoxymesterone resulted in significantly less appetite enhancement and did not have a favorable toxicity profile.8 The French Cooperative Group concluded that androgen therapy is truly efficient in moderately severe aplastic anaemia and that fluoxymesterone (1 mg/kg/d) for 18 months is to be chosen as the reference drug for any new androgen therapy assay.10

How Halotestin tablets are stored

The label says to store tablets at controlled room temperature of 20° to 25°C (68° to 77°F).1

Frequently asked questions

Is Halotestin a controlled substance?

The label says fluoxymesterone is a controlled substance under the Anabolic Steroids Control Act and that Halotestin tablets have been assigned to Schedule III.1

Is fluoxymesterone prohibited in sport?

The WADA Prohibited List names fluoxymesterone among the S1.1 anabolic androgenic steroids, in the S1 anabolic agents class it lists as prohibited at all times, in and out of competition.11

Is Halotestin still marketed?

Current marketing status was not established from the sources searched.

Is there dosing information beyond the label?

Beyond the label, the sources found are the trials in the table above and Capponi 1985, a six-subject bioavailability study; searches of DailyMed, ClinicalTrials.gov and PubMed found no newer label, no stability data and no dose trial in healthy people.2

References

  1. Pharmacia and Upjohn Company (DailyMed). Halotestin ® CIII fluoxymesterone tablets, USP. 2006. dailymed.nlm.nih.gov
  2. PubMed. Liquid chromatographic assay for fluoxymesterone in human serum with application to a preliminary bioavailability study. 1985. pubmed.ncbi.nlm.nih.gov
  3. PubMed. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. 2006. pubmed.ncbi.nlm.nih.gov
  4. PubMed. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. 1988. pubmed.ncbi.nlm.nih.gov
  5. PubMed. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. 1991. pubmed.ncbi.nlm.nih.gov
  6. PubMed. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. 1983. pubmed.ncbi.nlm.nih.gov
  7. PubMed. Long-term results of treatment with low-dose fluoxymesterone in constitutional delay of growth and puberty and in genetic short stature. 1993. pubmed.ncbi.nlm.nih.gov
  8. PubMed. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. 1999. pubmed.ncbi.nlm.nih.gov
  9. PubMed. Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. 1982. pubmed.ncbi.nlm.nih.gov
  10. PubMed. Androgen therapy in aplastic anaemia: a comparative study of high and low-doses and of 4 different androgens. French Cooperative Group for the Study of Aplastic and Refractory Anemias. 1986. pubmed.ncbi.nlm.nih.gov
  11. WADA. WORLD ANTI-DOPING CODE. wada-ama.org